processing speed

#AAN2018 – Siponimod Lessens Risk of SPMS Progression Independent of Relapses, Trial Data Show

Novartisā€™ investigational oral treatmentĀ siponimod (BAF312) reduces the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS), a new analysis of Phase 3 trial results show. Using what the company describes as more accurate methods to assess siponimod effect’s on progression risk, necessary because the…